# Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

> **NCT01251952** · PHASE1 · TERMINATED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Denileukin Diftitox (Ontak)

## Key facts

- **NCT ID:** NCT01251952
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2011-07
- **Final completion:** 2013-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Drug unavailable
- **Last updated:** 2017-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251952, "Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01251952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*